December 14, 2010

Press Release
Mitsubishi Tanabe Pharma Corporation

Commencement of R&D Partnership with Anaphore forAtrimerTM Technology (Novel Trivalent Proteins)
Mitsubishi Tanabe Pharma Corporation (head office: Osaka; President: Michihiro Tsuchiya)
announced today that it has entered into a basic agreement with Anaphore, Inc. (headoffice: California, U.S.A.; CEO: Katherine Bowdish) regarding R&D partnership to be
conducted between the parties, based on Atrimer™ technology possessed by Anaphore,
and that the research activities have commenced.
Atrimer™, novel trivalent proteins created by using the next-generation biologics technology
developed by Anaphore, is expected to become treatment for many diseases. Under theAgreement, Mitsubishi Tanabe Pharma and Tanabe Research Laboratories U.S.A.
(Mitsubishi Tanabe’s subsidiary, head office: San Diego, California, U.S.A.; “TRL”) willconduct joint research on Atrimer™ with Anaphore, with the aim of developing superior
biologic therapies for autoimmune disorders such as rheumatoid arthritis, inflammatory
bowel disease and psoriasis.
Since TRL is the Company's research center in San Diego, California (U.S.A.), theCompany decided in January 2010 to change TRL's research program from small moleculecompounds to biologics, considering the optimal use of the facilities in San Diego and theresources available to us in the United States, and potential research collaboration.

On theoccasion of this R&D partnership, TRL will accelerate biologics-based research programs.

Contact for further information:
Corporate Communications Department
Mitsubishi Tanabe Pharma Corporation
Phone: +81 6-6205-5211

(Reference)
Atrimer™
Anaphore's Atrimer™ is made from tetranectin, a protein of human origin. The three binding
domains of tetranectin are said to be capable of binding to any target by changing theirsterical structures. Anaphore possesses technology to structure an Atrimer™ library
exceeding 1011 by systematically changing these binding domains. It is said that by using
the strong binding ability of three binding domains, Atrimer™ binds to the target protein andexerts agonist or antagonist actions.

Anaphore, Inc.
Anaphore is developing a new class of protein pharmaceuticals to address significant unmet
medical needs for patients with serious diseases.

The company’s Atrimer™ technology

platform originates in tetranectin, a human plasma protein of trivalent structure. AtrimersTM
potentially offer biological, manufacturing, and commercial advantages over currently
marketed therapies.

Atrimer™ protein therapeutics are protected by intellectual property,including multiple patent families. Anaphore’s initial therapeutic focus is immunology andoncology.

In collaboration with select partners, Anaphore is committed to realizing the fullpromise of AtrimersTM against targets in a wide range of therapeutic areas, including rarediseases.
http://www.anaphore.com.
Address: 10931 N. Torrey Pines Road, Suite 101, La Jolla, San Diego, CA
Incorporated: 2008
Representative: Katherine S. Bowdish, Ph.D., Chief Executive Officer
Employees:

About 30 employees

Tanabe Research Laboratories U.S.A.
Tanabe Research Laboratories U.S.A. (TRL), an indirect wholly owned subsidiary of aMitsubishi Tanabe Pharma Corporation, is located in San Diego, California, U.S.A, as theoverseas research center of the Company. Celebrating its 20th anniversary this year, TRL
restarted as a research center specialized in development of biologics drugs forautoimmune disorders.
Address: 4540 Towne Centre Court, San Diego, CA
Incorporated: 1990
Representative: Masaki Yamada, President and CEO
Employees: About 13 employees2